Ketone esters for treatment of angelman syndrome
US9364456B1 · kind B1 · utility
4Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2015 |
| Grant date | Jun 14, 2016 |
| Priority date | — |
| Expiry date | Jun 30, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/225
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.